Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis

Nada Lelovic, Katsuhiko Mitachi, Junshu Yang, Maddie R. Lemieux, Yinduo Ji, Michio Kurosu

Research output: Contribution to journalArticle

Abstract

Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL-3) facility for performing research associated with Mtb is another limitation for the development of TB drug discovery. In our screening of BSL-1 Mycobacterium spp. against a battery of TB drugs, M. smegmatis (ATCC607) exhibits good agreement with its drug susceptibility against the TB drugs under a low-nutrient culture medium (0.5% Tween 80 in Middlebrook 7H9 broth). M. smegmatis (ATCC607) enters its dormant form in 14 days under a nutrient-deficient condition (a PBS buffer), and shows resistance to a majority of TB drugs, but shows susceptibility to amikacin, capreomycin, ethambutol, and rifampicin (with high concentrations) whose activities against non-replicating (or dormant) Mtb were previously validated.

Original languageEnglish (US)
JournalJournal of Antibiotics
DOIs
StateAccepted/In press - Jan 1 2020

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis'. Together they form a unique fingerprint.

  • Cite this